Resminostat
CAS: 864814-88-0
Ref. 3D-FR138825
| 1mg | A consultar | ||
| 2mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar |
Información del producto
- (2E)-3-[1-({4-[(Dimethylamino)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-hydroxyacrylamide
- (E)-3-[1-[[4-[(Dimethylamino)methyl]benzene]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxyacrylamide
- 4SC 201
- (2E)-3-[1-[[4-[(Dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-2-propenamide
- 2-Propenamide, 3-[1-[[4-[(dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-, (2E)-
Resminostat is a small molecule that inhibits the transcriptional co-activator, pd-l1. It has been shown to be very effective at reducing the growth of squamous cell carcinoma cells in vitro and in vivo. Resminostat also reduces liver fat content and steatosis by inhibiting fatty acid synthesis. Resminostat has been shown to induce apoptosis in cancer cells through inhibition of nuclear DNA replication, which leads to decreased production of proteins required for cell division. This drug has not been tested on humans but is being investigated as a potential treatment for hepatic steatosis, a condition characterized by excess fat accumulation in the liver.
Propiedades químicas
Consulta técnica sobre: 3D-FR138825 Resminostat
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
